Defining the Pathways Underlying the Prolonged PR Interval in Atrioventricular Conduction Disease

PLoS Genetics

Volumn 8, Issue 12, 2012, Pages

  Curran, Jerry ^a   Mohler, Peter J ^a  

^a OHIO STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CELL PROTEIN; SODIUM CHANNEL NAV1.5; TROPONIN I INTERACTING KINASE 3 PROTEIN; UNCLASSIFIED DRUG;

ARTICLE; ATRIOVENTRICULAR BLOCK; ATRIOVENTRICULAR CONDUCTION; CARDIOMYOPATHY; DISEASE SEVERITY; ENZYME PHOSPHORYLATION; FRAMINGHAM RISK SCORE; GAP JUNCTION; GENE; GENE FUNCTION; GENE OVEREXPRESSION; GENETIC SUSCEPTIBILITY; GENETIC VARIABILITY; HEART ATRIUM FIBRILLATION; HUMAN; MODIFIER GENE; MOLECULAR PATHOLOGY; NONHUMAN; PR INTERVAL; PROTEIN FUNCTION; QUANTITATIVE TRAIT LOCUS; SCN5A GENE; TROPONIN I INTERACTING KINASE 3 GENE;

ANIMALS; ATRIAL FIBRILLATION; ATRIOVENTRICULAR BLOCK; DISEASE MODELS, ANIMAL; ELECTROCARDIOGRAPHY; HUMANS; MICE; PROTEIN KINASES;

EID: 84872034355     PISSN: 15537390     EISSN: 15537404     Source Type: Journal    
DOI: 10.1371/journal.pgen.1003154     Document Type: Article

References (12)

1. Feinberg WM, Blackshear JL, Laupacis A, Kronmal R, Hart RG, (1995) Prevalence, age distribution, and gender of patients with atrial fibrillation. Analysis and implications. Arch Intern Med 155: 469-473.
2. Go AS, Hylek EM, Phillips KA, Chang Y, Henault LE, et al. (2001) Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study. JAMA 285: 2370-2375.
3. Krahn AD, Manfreda J, Tate RB, Mathewson FA, Cuddy TE, (1995) The natural history of atrial fibrillation: incidence, risk factors, and prognosis in the Manitoba Follow-Up Study. Am J Med 98: 476-484.
4. Wolf L, (1943) Familial auricular fibrillation. N Engl J Med 229: 396-397.
5. Fox CS, Parise H, D'Agostino RB Sr, Lloyd-Jones DM, Vasan RS, et al. (2004) Parental atrial fibrillation as a risk factor for atrial fibrillation in offspring. JAMA 291: 2851-2855.
6. Sinner MF, Ellinor PT, Meitinger T, Benjamin EJ, Kaab S, (2011) Genome-wide association studies of atrial fibrillation: past, present, and future. Cardiovasc Res 89: 701-709.
7. Darbar D, Herron KJ, Ballew JD, Jahangir A, Gersh BJ, et al. (2003) Familial atrial fibrillation is a genetically heterogeneous disorder. J Am Coll Cardiol 41: 2185-2192.
8. Lodder EM, Scicluna BP, Milano A, Sun AY, Tang H, (2012) Dissection of a quantitative trait locus for PR interval duration identifies Tnni3k as a novel modulator of cardiac conduction. PLoS Genet 8: e1003113 doi:10.1371/journal.pgen.1003113.
9. Remme CA, Scicluna BP, Verkerk AO, Amin AS, van Brunschot S, et al. (2009) Genetically determined differences in sodium current characteristics modulate conduction disease severity in mice with cardiac sodium channelopathy. Circ Res 104: 1283-1292.
10. Scicluna BP, Wilde AA, Bezzina CR, (2008) The primary arrhythmia syndromes: same mutation, different manifestations. Are we starting to understand why? J Cardiovasc Electrophysiol 19: 445-452.
11. Lai ZF, (2009) TNNI3K could be a novel molecular target for the treatment of cardiac diseases. Recent Pat Cardiovasc Drug Discov 4: 203-210.
12. Wheeler FC, Tang H, Marks OA, Hadnott TN, Chu PL, et al. (2009) Tnni3k modifies disease progression in murine models of cardiomyopathy. PLoS Genet 5: e1000647 doi:10.1371/journal.pgen.1000647.